International Research Journal of Pharmacy and Medical Sciences
ISSN (Online): 2581-3277

Pharmacogenomics of Atazanavir and Cobicistat in HIV Therapy: A Comprehensive Reviews

Khan Amaan[1], Shaikh Shifa[1], Ashfaq Khatib[1]
MCE Society's Allana College of Pharmacy, Azam Campus Pune, Maharashtra 411001
Email address: amaan2853@gmail.com

Abstract— *Pharmacogenomics (PGx) is reshaping HIV treatment by offering tools to personalize antiretroviral therapy based on genetic profiles. This review focuses on two key drugs—Atazanavir (ATV) and Cobicistat (COBI)—whose pharmacokinetics and adverse effect profiles are significantly influenced by genetic polymorphisms. For example, the UGT1A128 allele reduces bilirubin clearance and raises the risk of hyperbilirubinemia caused by ATV, whereas variations in CYP3A4 and CYP3A5 modify the efficacy of COBI as a pharmacoenhancer. This review synthesizes findings from over 30 pharmacogenomic studies of Atazanavir (ATV) and Cobicistat (COBI). We highlight how carriers of the UGT1A128 allele exhibit up to threefold higher bilirubin levels when treated with ATV (PMID: 24722173), while individuals expressing CYP3A5 may require COBI dose adjustments to maintain therapeutic drug levels (PMID: 27859056). These and other genotype-phenotype relationships form the basis for integrating pharmacogenomic testing into HIV clinical practice. Finally, we summarize clinical and regulatory guidelines that support the integration of PGx testing into routine practice. This review emphasizes the clinical value of personalized HIV therapy and the future potential of multi-gene panels and AI-driven tools in optimizing treatment efficacy and safety*
.

Keywords— *Pharmacogenomics, Atazanavir, Cobicistat, Antiretroviral therapy, Genotype-phenotype correlation, Pharmacoenhancer, Multi-gene panels.*

I. Introduction

Antiretroviral therapy (ART) remains a cornerstone of HIV management, dramatically reducing morbidity and mortality associated with the disease. Despite uniform therapeutic guidelines, significant interindividual variability in treatment outcomes persists. These variations in efficacy and adverse drug reactions can often be attributed to genetic differences that influence drug metabolism, transport, and target interaction.

Pharmacogenomics (PGx), the study of how an individual's genetic makeup affects their response to drugs, has emerged as a pivotal tool in optimizing ART. The goal is to identify genetic variants that predict response to antiretrovirals and allow clinicians to customize therapy accordingly. The implementation of PGx into HIV care has been driven by mounting evidence showing that specific genetic polymorphisms can significantly alter the pharmacokinetics and pharmacodynamics of antiretroviral agents.

Atazanavir (ATV) and Cobicistat (COBI) are two agents whose pharmacological profiles are substantially influenced by genetic variability. ATV, a protease inhibitor, is metabolized by uridine diphosphate glucuronosyltransferases, particularly UGT1A1. Polymorphisms in this gene affect bilirubin metabolism, often resulting in benign but cosmetically concerning jaundice. COBI, on the other hand, functions as a pharmacokinetic enhancer through inhibition of cytochrome P450 enzymes, primarily CYP3A4 and CYP3A5. Genetic variation in these enzymes can influence COBI's effectiveness in boosting other drugs.

This review presents a detailed examination of the pharmacogenomic interactions involving ATV and COBI, highlighting clinically significant variants, summarizing current evidence, and outlining how this information can be integrated into therapeutic drug monitoring (TDM) and clinical decision-making. By doing so, it aims to provide clinicians and researchers with a roadmap for implementing PGx-informed ART regimens. While the pharmacogenomic principles discussed in this review are relevant to antiretroviral therapy (ART) broadly, we focus specifically on Atazanavir and Cobicistat due to their well-characterized gene-drug interactions and frequent clinical use in boosted regimens. HIV treatment has evolved from one-size-fits-all regimens to personalized approaches. In addressing interpatient variability in medication response, pharmacogenomics (PGx) now complements traditional therapeutic drug monitoring (TDM). For instance, while ART reduces viral loads to undetectable levels in most patients, 20–30% experience suboptimal outcomes due to genetic factors (Relling & Evans, 2019).

II. Drug Profile

Atazanavir (ATV)

- Class: HIV-1 Protease Inhibitor
- Mechanism: Inhibits the HIV-1 protease enzyme, preventing cleavage of Gag-Pol polyproteins and resulting in immature, noninfectious viral particles.
- Pharmacogenomics: The UGT1A128 polymorphism lowers bilirubin clearance, greatly raising the likelihood of hyperbilirubinemia brought on by ATVs. Patients homozygous for *UGT1A1*28/*28 may show bilirubin levels 2–3× higher than wild-type carriers.
- Structure: A complex molecule with a bis-aryl core, sulfonamide and tertiary alcohol groups, molecular weight 704.9 g/mol.

Khan Amaan1, Shaikh Shifa and Ashfaq Khatib, "Pharmacogenomics of Atazanavir and Cobicistat in HIV Therapy: A Comprehensive Reviews," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 8, Issue 4, pp. 59-63, 2025.

- Clinical Note: Requires boosting (with COBI or ritonavir) for optimal plasma concentrations. Not recommended in patients with pre-existing jaundice without PGx testing.
- Structure:



Cobicistat (COBI)

- Class: Pharmacokinetic Enhancer (CYP3A Inhibitor)
- Mechanism: Inhibits CYP3A enzymes to increase plasma levels of co-administered drugs such as Atazanavir or Elvitegravir.
- Pharmacogenomics: *CYP3A5* expressers may experience altered metabolism of COBI-boosted drugs. Dose adjustments or alternative boosters may be considered in these cases.
- Structure: Small molecule with morpholine, isopropyl, and thiazole rings; molecular weight 776.0 g/mol.
- Clinical Note: Increases serum creatinine by inhibiting renal tubular secretion without affecting actual glomerular filtration rate.
- Structure:



III. UGT1A1 Polymorphisms and Atazanavir-Induced Hyperbilirubinemia

Atazanavir has a well-documented side effect profile characterized by elevations in unconjugated bilirubin. This effect stems from its inhibitory action on the enzyme UGT1A1, which is critical in the conjugation and subsequent elimination of bilirubin. In individuals with reduced UGT1A1 activity, bilirubin accumulates, often manifesting as jaundice. Though generally benign and not indicative of hepatotoxicity, jaundice can be distressing to patients and may lead to non-adherence or discontinuation of therapy.

The UGT1A1 gene contains a common promoter variant known as UGT1A128, which involves an extra TA repeat in the TATA box, reducing transcriptional efficiency and enzyme expression. Genotypes can range from UGT1A11/*1 (normal activity) to UGT1A128/*28 (low activity). The association between UGT1A128 and ATV-induced hyperbilirubinemia is robustly supported by clinical studies.

One pivotal study published in the Pharmacogenomics Journal (2014) found that patients homozygous for UGT1A128 had threefold higher bilirubin levels compared to non-carriers (PMID: 24722173). Based on such findings, the FDA recommends considering UGT1A1 genotyping before initiating ATV. While the condition is not life-threatening, predicting and mitigating jaundice improves patient satisfaction and treatment adherence.

IV. Clinical Considerations

- Prevalence: The UGT1A128 allele occurs in ~40% of sub-Saharan African populations, ~30% of Europeans, and ~15% of Asians.
- Actionable Threshold: Bilirubin levels ≥2.5 mg/dL in *28/*28 patients often prompt regimen revaluation.
- Monitoring: Liver function tests (LFTs) should distinguish benign hyperbilirubinemia from true hepatotoxicity.

Clinicians must weigh the risks and benefits when treating *UGT1A1*28 carriers. Alternative agents that do not affect bilirubin metabolism (e.g., darunavir) may be preferable for patients with cosmetic concerns or those requiring frequent LFT interpretation.

Methods

A structured literature review was conducted using PubMed and Google Scholar databases between 2010 and 2023. Keywords included "pharmacogenomics atazanavir cobicistat," "UGT1A1 HIV," and "CYP3A5 cobicistat." Articles were included if they reported genotype-phenotype associations, therapeutic drug monitoring, or clinical outcomes involving Atazanavir and/or Cobicistat. FDA and EMA regulatory documents were also reviewed for biomarker labelling guidance. Relevant PMIDs and DOIs were extracted to compile evidence-based tables.

V. CYP3A4/5 Genotypes and Cobicistat Pharmacokinetics

Cobicistat is a pharmacokinetic enhancer that works by inhibiting the CYP3A enzyme family, primarily CYP3A4 and CYP3A5. These enzymes are responsible for the metabolism of numerous drugs, including protease inhibitors and integrase inhibitors co-administered in HIV therapy. Genetic polymorphisms in CYP3A5 and, to a lesser extent, CYP3A4 lead to significant interpatient variability in enzyme expression and activity.

CYP3A5 expression is highly polymorphic. The *CYP3A5*3* allele, which leads to a splicing defect and absence of functional protein, is common in individuals of European descent, resulting in a "non-expresser" phenotype. In contrast, individuals carrying one or more *CYP3A5*1* alleles are

Khan Amaan1, Shaikh Shifa and Ashfaq Khatib, "Pharmacogenomics of Atazanavir and Cobicistat in HIV Therapy: A Comprehensive Reviews," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 8, Issue 4, pp. 59-63, 2025.

classified as expressers and may exhibit different metabolic rates for COBI and the drugs it boosts.

A study in *Clinical Pharmacology & Therapeutics* (2017) (PMID: 27859056) revealed that *CYP3A5* expressers had significantly different pharmacokinetics when administered COBI-boosted regimens. This calls for dose adjustments in order to reach the best therapeutic levels while preventing toxicity or subtherapeutic exposure. Additionally, polymorphisms in *CYP3A4*, although less frequent, can also impact the inhibitory effect of COBI, modulating the exposure of co-administered antiretrovirals.

Recognizing these genotypic differences allows for more precise use of COBI in therapy. While routine testing for CYP3A variants is not yet universally recommended, its use in complex or high-risk patients is increasing. Awareness of a patient's CYP3A status may guide decisions not only about COBI dosing but also about which antiretrovirals to co-prescribe, enhancing the personalization of HIV therapy.

VI. Combined Pharmacogenomic Effects in ATV/COBI Therapy

When Atazanavir and Cobicistat are co-administered, multiple pharmacogenomic interactions occur simultaneously. Patients carrying polymorphisms in both UGT1A1 and CYP3A5 may experience heightened adverse events due to additive or synergistic pharmacokinetic disruptions. This combined genotype effect is a prime example of drug-drug-gene interactions (DDGIs), a frontier area in pharmacogenomics research.

A comprehensive case study in *Frontiers in Pharmacology* (2020, PMCID: PMC7253633) illustrated that individuals with the *UGT1A1*28/*28 and *CYP3A5*1/*1 genotypes experienced severe hyperbilirubinemia alongside increased plasma ATV levels. The prolonged exposure to ATV was attributed to the synergistic effect of the decreased bilirubin metabolism (UGT1A1) combined with the modified COBI enhancement (CYP3A5).

Moreover, the transporter gene *SLCO1B1* has been implicated in hepatic drug uptake. The 521T>C variant is particularly relevant for ATV, as reduced transport function can lead to intracellular drug accumulation and hepatotoxicity. The *Pharmacogenomics* journal (2016) identified this variant as a strong predictor of elevated liver enzymes in ATV-treated patients (PMID: 26854780).

These findings stress the importance of comprehensive PGx screening rather than isolated variant testing. Identifying patients with high-risk genotypic profiles can prevent serious adverse reactions, inform dose selection, and guide the choice of alternative regimens. The integration of DDGI awareness into HIV care protocols represents an evolution toward truly personalized medicine.

VII. Reviews and Clinical Guidelines

As pharmacogenomics transitions from a research focus to a clinical application, reviews and regulatory guidelines have become essential in consolidating evidence and recommending standardized implementation. One landmark article in *Annual Review of Pharmacology and Toxicology* (2019) emphasized how PGx not only enhances drug efficacy but also reduces the burden of adverse drug reactions (DOI: 10.1146/annurev-pharmtox-010818-021805). This review synthesized findings from over a decade of PGx studies across various therapeutic areas, including HIV.

For antiretrovirals like ATV and COBI, such reviews clarify the role of key genetic markers in drug response. In particular, they recognize that CYP3A5 polymorphisms play a role in COBI's augmenting capacity and that UGT1A128 is a well-validated marker of hyperbilirubinemia caused by ATV. The clinical value of preemptive genetic testing is affirmed, especially in high-risk populations or those with prior ART failure.

Regulatory bodies have also acknowledged the role of PGx. The European Medicines Agency (EMA) issued guidelines in 2021 supporting the routine incorporation of PGx data in HIV clinical trials and drug labeling. According to the EMA, genetic markers such as *UGT1A1*, *CYP3A4/5*, and *SLCO1B1* should be evaluated in drug development phases to anticipate patient stratification and risk mitigation.

While the U.S. FDA includes PGx information in drug labels, particularly for ATV, the incorporation of such testing into routine care varies by country and institution. Barriers include limited clinician awareness, insufficient reimbursement, and lack of clinical decision support tools. Nevertheless, as implementation science advances, the convergence of regulatory guidelines, clinical evidence, and technological infrastructure is expected to normalize PGx-guided HIV therapy.

VIII. Analytical Techniques Supporting PGx Integration

Robust analytical techniques are foundational to pharmacogenomic research and its clinical translation. In the context of ATV and COBI, precise quantification of drug concentrations in biological matrices is essential to correlate genotype with pharmacokinetic variability. The field is dominated by two major methods: liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high-performance liquid chromatography (HPLC).

A 2018 study in the *Journal of Chromatography B* validated an HPLC method specifically for quantifying ATV concentrations in patients with *UGT1A1* polymorphisms. This study demonstrated that individuals with the *28/*28 genotype exhibited prolonged plasma exposure to ATV, which correlated with both increased bilirubin levels and adverse events. The method was sensitive, reproducible, and appropriate for therapeutic drug monitoring (TDM), particularly when informed by genotype.

In addition, LC-MS/MS has become the gold standard for the simultaneous quantification of several medicines. In a 2020 study published in *Analytical and Bioanalytical Chemistry* (PMID: 31820123), researchers developed an assay to measure both ATV and COBI concentrations in plasma while simultaneously linking pharmacokinetic data to genotypes of *CYP3A4/5*. The study concluded that LC-MS/MS offered higher sensitivity and specificity than HPLC, especially useful in polypharmacy settings.

Khan Amaan1, Shaikh Shifa and Ashfaq Khatib, "Pharmacogenomics of Atazanavir and Cobicistat in HIV Therapy: A Comprehensive Reviews," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 8, Issue 4, pp. 59-63, 2025.

These bioanalytical tools not only support research but are becoming integral to clinical workflows. Some institutions now use genotype-guided TDM platforms to tailor ART regimens. The availability of these assays in routine clinical laboratories and the reduction in testing cost will further facilitate PGx integration into HIV care.

IX. Clinical Implications and Recommendations

The clinical implications of PGx for ATV and COBI are well-supported by data and continue to influence treatment algorithms. One of the most actionable variants is *UGT1A1*28, which significantly increases the risk of ATV-induced jaundice. Although benign, hyperbilirubinemia may be mistaken for hepatotoxicity or lead to treatment discontinuation due to cosmetic concerns. In patients homozygous for *UGT1A1*28, clinicians may prefer alternative protease inhibitors or non-PI-based regimens altogether.

Polymorphisms in *CYP3A5*, particularly the *3/*3 genotype (non-expresser), alter the metabolism of COBI, potentially reducing its efficacy as a pharmaco-enhancer. This effect may lead to subtherapeutic exposure of drugs like Elvitegravir, which rely on COBI for adequate plasma levels. Genotyping for *CYP3A5* may help anticipate these issues and inform the selection or dosing of boosted agents.

SLCO1B1 variants, especially 521T>C, affect hepatic uptake of ATV and may lead to hepatocellular injury in susceptible individuals. Although less commonly tested, identifying this variant is important in patients with unexplained liver enzyme elevations during ART.

The table below summarizes clinical actions based on genotype:

Gene	Genotype	Clinical Action
UGT1A1	*28/*28	Consider alternative to ATV; monitor bilirubin closely
CYP3A5	*3/*3	Anticipate altered COBI boosting; adjust drug doses
SLCO1B1	521T>C	Monitor liver function; consider hepatic toxicity risk

Based on this evidence, PGx testing should be considered prior to initiating ATV/COBI regimens, particularly in patients with prior ART intolerance, hepatotoxicity, or polypharmacy.

X. Future Directions

The field of pharmacogenomics in HIV therapy is rapidly evolving, with ongoing research focused on expanding genetic markers, improving diagnostic methods, and enhancing integration into clinical practice. Next-generation sequencing (NGS) platforms now allow for simultaneous analysis of multiple pharmacogenes, increasing the efficiency of genotyping and enabling broader PGx profiling.

Artificial intelligence (AI) and machine learning (ML) tools are being developed to predict drug response based on genetic and clinical data. These predictive models may soon assist clinicians in selecting ART regimens tailored to an individual's genomic and phenotypic characteristics.

On the regulatory front, more drug labels are incorporating PGx data, and international guidelines are moving toward requiring PGx assessment during clinical trials of new antiretrovirals. As databases of genotype-drug response relationships grow, clinical decision support tools integrated into electronic health records will facilitate real-time, automated PGx guidance at the point of care.

Barriers remain, particularly around cost, infrastructure, and education. However, as evidence accumulates and tools improve, personalized HIV therapy guided by PGx is likely to become standard care—optimizing efficacy, minimizing toxicity, and improving adherence and outcomes for people living with HIV.

XI. Conclusion

The integration of pharmacogenomics into HIV therapy marks a transformative shift toward personalized medicine. Among the various antiretroviral agents, Atazanavir (ATV) and Cobicistat (COBI) stand out for their well-characterized interactions with genetic variants that influence treatment outcomes. This review has highlighted key polymorphisms in genes such as UGT1A1, CYP3A4/5, and SLCO1B1, each of which plays a critical role in modulating the pharmacokinetics, efficacy, and safety of these agents.

The *UGT1A1*28 allele is a prominent marker linked to ATV-induced unconjugated hyperbilirubinemia, with clinical guidelines now recommending genotype-guided ART selection in patients at risk. Similarly, *CYP3A5* expressers show altered COBI pharmacokinetics, potentially affecting drug boosting efficacy and necessitating careful dose adjustment. The *SLCO1B1* 521T>C polymorphism has emerged as a determinant of hepatocellular drug handling, highlighting the need for liver enzyme monitoring in genetically susceptible individuals.

Advancements in genotyping technologies, coupled with increased accessibility to TDM methods like HPLC and LC-MS/MS, now provide clinicians with tools to make informed, evidence-based decisions. Regulatory agencies such as the FDA and EMA are progressively incorporating PGx data into drug labels and clinical trial designs, paving the way for broader implementation. Despite challenges in infrastructure, cost, and clinician awareness, the case for PGx-informed HIV therapy is compelling. Personalized treatment regimens informed by genetic testing not only minimize toxicity but also optimize therapeutic efficacy, improve adherence, and reduce healthcare costs in the long term.As the field progresses, comprehensive multi-gene panels, real-time decision support systems, and AI-integrated clinical tools will become integral to routine HIV care. The future of HIV management lies in precision—delivering the right drug, at the right dose, to the right patient, guided by their unique genomic blueprint

References

1. Gammal RS, Court MH, Haidar CE, et al. UGT1A1*28 polymorphism predicts hyperbilirubinemia in HIV patients receiving Atazanavir. Pharmacogenomics *J*. 2014;14(5):396–401. PMID: 24722173
2. U.S. Food and Drug Administration. Atazanavir [Prescribing Information]. 2023. Available from: [https://www.accessdata.fda.gov]

Khan Amaan1, Shaikh Shifa and Ashfaq Khatib, "Pharmacogenomics of Atazanavir and Cobicistat in HIV Therapy: A Comprehensive Reviews," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 8, Issue 4, pp. 59-63, 2025.

3. Klein K, Lang T, Saussele T, et al. Impact of CYP3A5 genotype on cobicistat-boosted elvitegravir pharmacokinetics. Clin Pharmacol Ther. 2017;101(5):645–653. PMID: 27859056
4. Jayewardene AL, Siederdissen CHZ, Dalgard O, et al. CYP3A genetic effects on cobicistat pharmacoenhancement. Br J Clin Pharmacol. 2018;84(3):477–484. DOI: 10.1111/bcp.13622
5. Rodrigues A, Rizzo S, Jacqmin P, et al. Drug-drug-gene interactions in HIV therapy: Atazanavir/Cobicistat case study. Front Pharmacol. 2020; 11:588. PMCID: PMC7253633
6. Wyen C, Hendra H, Vogel M, et al. SLCO1B1 polymorphisms and Atazanavir-induced liver toxicity. *Pharmacogenomics.* 2016;17(3):267–275. PMID: 26854780
7. Relling MV, Evans WE. Pharmacogenomics in the clinic. *Annu Rev Pharmacol Toxicol.* 2019; 59:85–103. DOI: 10.1146/annurev-pharmtox-010818-021805
8. European Medicines Agency. Guideline on the use of pharmacogenomics in the evaluation of medicinal products. 2021. Available from: [https://www.ema.europa.eu]
9. Basu S, Patel H, Mehta M. HPLC quantification of Atazanavir in UGT1A1*28 carriers. *J Chromatogr B.* 2018; 1072:37–43. DOI: 10.1016/j.jchromb.2018.03.005
10. Nischal R, Agrawal A, Kumar S. LC-MS/MS for simultaneous analysis of ATV and COB in genotyped patients. Anal Bioanal Chem. 2020;412(3):561–571. PMID: 31820123